AI Article Synopsis
- * VHE can lead to serious symptoms such as impaired consciousness (from drowsiness to coma), more frequent seizures, cognitive difficulties, and digestive issues.
- * This study presents a case of VHE and reviews 20 previous cases in Chinese patients to identify risk factors, emphasizing the importance of monitoring serum ammonia levels and the need to stop VPA as the main treatment for VHE.
Article Abstract
Valproate (VPA) is a medication that is widely used in the treatment of neurological and psychiatric disorders, such as epilepsy and bipolar disorder. Valproate-induced hyperammonemic encephalopathy (VHE) is a rare central nervous system adverse effect of this medication that is characterized by impaired consciousness, which can range from drowsiness to coma; increased seizure frequency; acute cognitive symptoms; and gastrointestinal symptoms. In this manuscript, we report a single case and also review previous cases of VHE (n=20) in Chinese patients to identify risk factors for VHE. Increasing clinicians' awareness of VHE during concomitant VPA therapy is of utmost importance. Serum ammonia level is a useful and important diagnostic test. The discontinuation of VPA is currently the mainstay of treatment for VHE.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.comppsych.2012.11.001 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!